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Incidence and drug treatment of emotional distress after cancer
diagnosis: a matched primary care case–control study
F Desplenter*,1,2, C Bond1, M Watson1, C Burton1, P Murchie1, AJ Lee3, K Lefevre1, S Simoens2
and G Laekeman2
1Academic Primary Care, University of Aberdeen, Foresterhill, Polwarth Building, Aberdeen AB25 2ZD, UK; 2Department of Pharmaceutical and
Pharmacological Sciences, ON 2, Herestraat 49, PO Box 521, 3000 Leuven, Belgium; 3Medical Statistics Team, University of Aberdeen, Foresterhill,
Polwarth Building, Aberdeen AB25 2ZD, UK
BACKGROUND: Emotional distress is common in cancer patients. This study aimed to describe, in the year after a cancer diagnosis: the
incidence of anxiety, depression and excessive alcohol use; the pattern of these diagnoses and treatment over time; and the nature
and duration of the prescribed treatment.
METHODS: A matched case–control study was conducted using routinely collected primary care data from 173 Scottish general
practices. A presumptive diagnosis of emotional distress (anxiety, depression and/or excessive alcohol use) was based on prescription
data or diagnostic code. Prescriptions for psychotropic drugs were described in terms of drug class, volume and treatment duration.
RESULTS: In total, 7298 cancer cases and 14 596 matched-controls were identified. Overall, 1135 (15.6%) cases and 201 (1.4%)
controls met criteria for emotional distress (odds ratio 13.7, 95% confidence interval 11.6–16.1). Psychotropic drugs were prescribed
in the 6 months following initial cancer diagnosis for 1066 (14.6%) cases and 161 (1.1%) controls. The volume and duration of
anxiolytic and antipsychotic prescribing was significantly different between cases and controls.
CONCLUSION: This study quantified the higher incidence of new emotional distress in cancer patients in the first year post diagnosis.
Clinicians should be aware of the possibility of emotional distress at any time in the year after cancer diagnosis.
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Depression and anxiety are common in patients with cancer
(Massie, 2004; Sharpe et al, 2004; Vahdaninia et al, 2010), may
occur and be diagnosed at any stage of the cancer journey (Miovic
and Block, 2007; Hansen and Sawatzky, 2008) and are estimated to
affect up to 40% of people with cancer. About 50% of patients with
advanced cancer meet criteria for a psychiatric diagnosis if
adjustment disorder is included (Massie, 2004). Newly diagnosed
alcohol abuse after cancer diagnosis is a further indication of the
emotional impact of the condition (Bringmann et al, 2008; Yung
and Piccirillo, 2008). Both depression and anxiety are amenable to
treatment, both pharmacologically and using cognitive behavioural
approaches (Strong et al, 2008; Deshields and Nanna, 2010;
Holland and Alici, 2010; Wein et al, 2010).
Although secondary care is largely responsible for cancer-specific
treatment such as surgery or chemotherapy, most general and
supportive care of cancer patients takes place in primary care (Lewis
et al, 2009). This is also where the majority of treatment for
depression and anxiety takes place (Munoz-Arroyo et al, 2006;
Hodges et al, 2009). While consultation rates for coded depression or
anxiety have been reported to be similar to those of the general
population in long-term survivors of common cancers in the UK,
there is an increase in the proportion receiving at least one
prescription for an antidepressant, indicating increased mental health
morbidity (Khan et al, 2010). However, it is not clear at which stage of
the cancer journey this excess mental health morbidity occurs.
The aim of this study was to describe, in the first year following
a cancer diagnosis in subjects without a pre-existing mental health
condition: (a) the incidence of three common mental health
problems: depression, anxiety and excessive alcohol use, using a
combination of prescription data and diagnostic codes; (b) the
pattern of these problems and treatment over time; and (c) the
nature and duration of prescribed treatment. Throughout this
paper, one or any combination of the above three problems is
referred to as emotional distress.
MATERIALS AND METHODS
Design
A matched case–control study was conducted, using routinely
collected primary care data (http://www.abdn.ac.uk/pcciu/
PCCIU.htm).
Subjects and setting
Data from 173 general practices in Scotland was obtained from the
Primary Care Clinical Informatics Unit (PCCIU), University of
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Aberdeen. The PCCIU data comprised anonymised extracts from
173 practices, which used the General Practice Administration
System for Scotland (GPASS) software (NHS Scotland, Glasgow,
UK). The data for this study was obtained by running specified
queries against the Microsoft SQL server holding the extracted
general practitioners (GP) data and transferring this into a SPSS
database (version 18 for Windows, SPSS Inc., Chicago, IL, USA).
The study period was 1 April 2005–1 April 2010, and data were
available for 1 026 770 patients.
Inclusion and exclusion criteria
Cases were defined as individuals aged 18 years and older with a
diagnosis of one of eight cancer types, selected for their high
incidence in the UK: breast, colorectal, lung, prostate, upper
gastro-intestinal, melanoma (excluding non-melanoma skin can-
cers), gynaecological and urological cancers (Cancer Research UK,
2011). Controls were matched according to gender, age (5-year age
bands) and general practice. Patients with any cancer diagnosis
were excluded from the control group. Patients with a diagnosis of
depression, anxiety or excessive alcohol use or who had used
antidepressants, anxiolytics or medicines for alcohol dependence
in the year before the index date, that is, the date of cancer
diagnosis for each individual case, were excluded from both the
cases and their matched controls.
Subject identification
The GPASS clinical system utilises the READ V2 clinical
terminology for the recording of patient findings, diagnoses and
procedures. READ codes are a coded thesaurus of clinical terms
(http://www.connectingforhealth.nhs.uk/systemsandservices/data/
uktc/readcodes). READ codes have two versions: Version 2 (v2)
and version 3 (CTV3 or v3), which are the basic means by which
clinicians record patient findings and procedures in health and
social care IT systems across primary and secondary care (e.g.,
general practice surgeries and pathology reporting of results).
READ codes have been in use in the NHS since 1985 and are still
widely used in the primary care sector. Scottish primary care
exclusively uses Read V2. They are maintained by the UK
Terminology Centre. Cross-maps are maintained from the Read
codes to the UK-mandated classifications of OPCS-4 and ICD-10
Pathology Bounded Code List. Code sets to identify cancer cases
and the diagnoses of depression, anxiety and excessive alcohol use
were developed from the Scotland READ V2 browser released in
Spring 2010. Prescription of antidepressants, anxiolytics or
medicines for alcohol dependence was defined by the British
National Formulary (BNF) 59 chapter sections 4.3.1–4.3.4 (anti-
depressants), 4.1.2 (anxiolytics) and 4.10 (subsection alcohol
dependence) (2010).
A 1 : 2 case–control matching ratio was applied. Hence, each
cluster comprised one case and two-matched control patients. The
following criteria were then applied (Figure 1). First, cases without
sufficient matching control patients were excluded. Second,
clusters which included patients with multiple cancer diagnoses
at first date of diagnosis were excluded if no clinical evidence was
available to identify the first diagnosed cancer thus preventing
stratification according to index cancer site. Third, only clusters
with an index date earlier than 1 October 2008 were included to
allow for 18 months of follow-up data for the outcome assessment.
Finally, clusters which included at least one patient who had died
before the index date were excluded.
Outcome
The primary outcome was the composite measure of emotional
distress (i.e., anxiety, depression and/or excessive alcohol use).
The secondary outcome was the prescription of psychotropic
drugs in the first 6 months after the diagnosis of emotional
distress. For this secondary outcome we included drugs listed as
indicating emotional distress plus those in BNF chapter sections
4.1.1 (hypnotics), 4.2.1 (antipsychotics) and 4.2.3 (anti-manics).
For each patient we recorded the type of drug, the total quantity
prescribed (expressed as total DDDs (defined daily dose) (WHO,
2010)) and treatment duration.
Data specification
For each patient we extracted data on gender, age, socioeconomic
deprivation (seven categories of the Carstairs index (Morris and
Carstairs, 1991)), urban/rural status (six-fold classification of the
Scottish Index of Multiple Deprivation 2006 at practice level
(Office of the Chief Statistician, 2006)), smoking (never smoked,
ex-smoker and current smoker according to the latest registration
of READ codes) and date of death (if relevant). For cases, data on
registration in the Palliative Care Register (an indicator for the
cancer stage) was also extracted.
For each prescription in the 6-month follow-up period, we
extracted the generic drug name, the date of issue, the strength, the
dose and the frequency. Estimated daily doses were translated into
DDDs (Burton et al, 2012), using the WHO standard values (WHO,
2010). Total duration of treatment in days was calculated by
subtracting the date of the last prescription from the date of the
first prescription and adding the actual duration of the last
prescription. Total DDDs prescribed and duration was calculated
per patient for drug groups and subgroups of interest. Liquid
preparations (about 1% of the psychotropic drug prescriptions)
were excluded from the database as calculations for volume and
treatment duration were unreliable. In reporting medication use in
patients who met our criteria for emotional distress, we did not
attempt to distinguish between use for a primary psychiatric
condition or for other indications such as pain (tricyclic
antidepressants) or nausea (typical antipsychotics) as this
information is not available in the database.
Standard methods of data cleaning and validation were applied.
The internal reliability of the data was checked by searching and
checking the type of data received and the outliers for each
variable.
The North of Scotland Research Ethics Committee was
contacted to determine whether formal ethical approval was
required for this study. As the data used was anonymous at every
stage of the research process full formal ethical approval was not
required.
Statistical analysis
Descriptive analyses (frequencies for categorical variables, mean
and s.d. for normally distributed continuous data, and median and
inter quartile range for non-normally distributed continuous data)
were conducted. Demographic characteristics and incidence rates
were compared between cases and controls using conditional
logistic regression. Odds ratios (OR) and the 95% confidence
intervals (CI) were reported. Matched survival analysis (using a
stratified COX model) (Cox, 1972) was used to produce Kaplan–
Meier graphs to illustrate the timeline of incident emotional
distress. The assumption of proportionality was tested and met.
Analysis was completed for the time from index date up to 1 year,
using death as a censoring variable. The w2 test was used to
compare the proportions of drugs (and drug groups) and to
compare the frequencies of users of psychotropic drugs between
cases and controls. When numbers were small, Fisher’s Exact test
was used instead of the w2 test. The Mann–Whitney U-test was
used to compare the quantity and the duration of prescriptions
between cases and controls.
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Data handling and analyses were performed using PASW Statistics
19.0 (Predictive Analytics SoftWare) for Windows (2010, SPSS Inc.).
STATA 11 (2009, STATA, TX, USA) was used for the conditional
logistic regression and the stratified COX model.
RESULTS
Sample
Based on the inclusion and exclusion criteria and the subject
identification process, 7298 cancer cases and 14 596 matched-
controls were identified (Figure 1). Sample characteristics are
summarised in Table 1. Half of the sample was female (50.7%). The
mean age was 67.4 years. No statistically significant differences
between cases and controls were observed for deprivation. The
proportion of ex-smokers (OR 1.57 (95% CI 1.48–1.68)) and
smokers (OR 1.35 (95% CI 1.24–1.46)) was significantly higher
among cases. A higher proportion of cases died within 12 months
(OR 99.5 (95% CI 47.1–210.3)) and within 18 months (OR 52.1
(95% CI 31.6–85.9)) of index date.
Incidence of emotional distress
Overall, 1135 (15.6%) cases and 201 (1.4%) controls were identified
with emotional distress within 1 year following the index date
765 427 Patients without 
cancer diagnosis
14 899 Patients with one of the eight 
cancer diagnoses
(1 April 2005 – 1 April 2010)
525 363 Available control patients
11 011 Cases
371 576 Available control patients
Match on age +/–5 years 
(1 April 2005), gender, 
practice ID
240 064 (31.4%) exclusions
808 702 Adult patients 
registred on 1 April 2004
3888 (26.1%) Distinct 
patient exclusions of 4987 
exclusions in total 
(a)
153 787 (29.3%) Distinct 
patient exclusions of 
231 839 exclusions in total 
(a)
Exclusions for 1 year prior 
depression:
27 369 (5.2%) based on diagnosis
111 185 (21.2%) based on 
prescription
30 165 Matched-controlled patients
10 066 Cases20 132 Matched-controls Ratio 1: 2
10 048 Cases20 096 Matched-controls
Exclusion of clusters (n=18) with multiple 
cancer diagnoses at first date (b)
7 301 Cases14 602 Matched-controls
Exclusion of clusters (n=2747) with cancer
diagnosis after 30 Septembar 2008  (b)
7 298 Cases14 596 Matched-controls
Exclusion of clusters (n=3) with 
patients died before index date (b)
1 026 770 Live patients at data collection
(bi-annually) 1 April 2005 – 1 April 2010
Exclusions for 1 year prior
anxiety:
15 705 (3.0%) based on diagnosis
45 439 (8.6%) based on prescription
Exclusions for 1 year prior
alcohol dependence:
30 706 (5.8%) based on diagnosis
1435 (0.3%) based on prescription
Exclusions for 1 year prior
depression:
312 (2.1%) Based on diagnosis
2546 (17.1%) Based on prescription
Exclusions for 1 year prior
anxiety:
236 (1.6%) Based on diagnosis
1105 (7.4%) Based on prescription
Exclusions for 1 year prior
alcohol dependence:
770 (5.2%) based on diagnosis
18 (0.1%) based on prescription
(a) The sum of the numbers in the exclusion boxes below do not add up owing to duplicate patients.
(b) Exclusion made at case level.
28 376 Patient exclusions 
with non–targeted cancer 
diagnosis
201 Patients with anxiety/anxiolytics -
depression/antidepressant – excessive 
alcohol use/disulfiram/acamprosate
161 Patients with prescriptions for
psychotropic drugs
1066 Patients with prescriptions for
psychotropic drugs
1135 Patients with anxiety/anxiolytics -
depression/antidepressant – excessive 
alcohol use/disulfiram/acamprosate
Figure 1 Flow chart of sample.
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(Table 2). The overall OR for emotional distress between cases and
controls was 13.66 (95% CI 11.59–16.11). When comparing cases
with controls, the OR for the incidence of anxiety and/or
anxiolytics was 14.32 (95% CI 11.23–18.26) (537 (7.4%) cases vs
84 (0.6%) controls); for depression and/or antidepressants 13.84
(95% CI 11.24–17.03) (713 (9.8%) cases vs 112 (0.8%) cases); and
for excessive alcohol use and/or disulfiram/acamprosate 4.07 (95%
CI 2.57–6.46) (55 (0.8%) cases vs 27 (0.2%) controls).
The Kaplan–Meier graphs (Figure 2) illustrate the time from the
index date to identification of emotional distress. The figures show
that during the 1-year period post index cancer diagnosis there was
no specific time point at which indicators of emotional distress, as
previously defined, were recorded.
Psychotropic drug prescriptions in the 6 months after the
diagnosis of emotional distress
Psychotropic drugs were prescribed for 1066 (14.6%) cases and 161
(1.1%) controls in the 6-month period after initial diagnosis
(Table 3). Cases were prescribed more psychotropic drugs
(Po0.001) and more psychotropic drug groups (Po0.001). The
majority of the controls used one psychotropic drug (80.7%) or
drug group (85.1%) compared with 61.8% and 64.1%, respectively,
among cases. Of the individuals prescribed psychotropic drugs,
prescriptions for antidepressants were issued in 64.9% (n¼ 692) vs
62.7% (n¼ 101) controls (P¼ 0.589), anxiolytics in 46.5%
(n¼ 496) of cases vs 37.9% (n¼ 61) of controls (P¼ 0.040),
hypnotics in 22.7% (n¼ 242) vs 7.5% (n¼ 12) (Po0.001),
antipsychotics in 8.8% (n¼ 94) vs 6.2% (n¼ 10) (P¼ 0.268) and
anti-manic drugs in 0.9% (n¼ 14) vs 1.1% (n¼ 2) (P¼ 1.000).
The total prescribing volume and duration of psychotropic drug
prescriptions in the 6-month follow-up period is listed in Table 4.
These values were significantly different between the cohorts for
anxiolytic and antipsychotic drugs. Anxiolytics were prescribed in
greater volume (P¼ 0.017) and for a longer time (P¼ 0.003) in
cases. The opposite was observed for antipsychotic drugs, which
were prescribed in smaller volumes (P¼ 0.041) and for shorter
periods (P¼ 0.002) in cases. Hypnotic, antidepressant and anti-
manic prescriptions were comparable between cases and controls.
DISCUSSION
Summary of findings
Patients diagnosed with cancer were at least 10 times more likely
than matched controls to be diagnosed with emotional distress in
the year following a cancer diagnosis. The first coded diagnosis or
Table 1 Demographic and clinical characteristics of the casesa and controls
Cases (n¼ 7298) % (n) Controls (n¼ 14 596) % (n) Total (n¼ 21 894) % (n) OR (95% CI)
Age (mean (s.d.)) 68.2 (12.8) 67.0 (13.4) 67.4 (13.2) b
Female gender 50.7 (3703) 50.7 (7406) 50.7 (11109) b
Deprivation
DepCat1 (least deprived) 6.4 (464) 6.1 (887) 6.2 (1351) Reference
DepCat2 11.1 (812) 11.6 (1696) 11.5 (2508) 0.88 (0.74–1.04)
DepCat3 20.0 (1462) 20.6 (3004) 20.4 (4466) 0.90 (0.77–1.05)
DepCat4 31.6 (2303) 31.0 (4522) 31.2 (6825) 0.98 (0.84–1.14)
DepCat5 15.5 (1128) 15.6 (2283) 15.6 (3411) 0.94 (0.79–1.11)
DepCat6 11.7 (853) 11.5 (1677) 11.6 (2530) 0.99 (0.82–1.18)
DepCat7 (most deprived) 3.8 (276) 3.6 (527) 3.7 (803) 1.04 (0.81–1.34)
Urban/Rural status
Large urban 35.6 (2595) 35.6 (5190) 35.6 (7785) b
Other urban 37.2 (2716) 37.2 (5432) 37.2 (8148) b
Accessible small town 12.7 (925) 12.7 (1850) 12.7 (2775) b
Remote small town 7.7 (560) 7.7 (1120) 7.7 (1680) b
Accessible rural 4.0 (292) 4.0 (584) 4.0 (876) b
Remote rural 2.9 (210) 2.9 (420) 2.9 (630) b
Smoking status
Non-smoker 37.8 (2759) 47.0 (6863) 43.9 (9622) Reference
Ex-smoker 44.8 (3268) 36.6 (5336) 39.3 (8604) 1.57 (1.48–1.68)
Smoker 17.4 (1271) 16.4 (2397) 16.8 (3668) 1.35 (1.24–1.46)
Died within 12 months of index date 4.9 (358) 0.1 (20) 1.7 (378) 99.5 (47.1–210.3)
Died within 18 months of index date 5.9 (429) 0.2 (32) 2.1 (461) 52.1 (31.6–85.9)
Palliative care register 7.0 (510) 0 (0) – –
Cancer site
Breast 21.2 (1548) 0 (0) – –
Colorectal 17.4 (1271) 0 (0) – –
Lung 17.8 (1296) 0 (0) – –
Prostate 14.5 (1061) 0 (0) – –
Upper gastro-intestinal 7.4 (537) 0 (0) – –
Melanoma 5.5 (402) 0 (0) – –
Gynaecological 6.1 (447) 0 (0) – –
Urological 10.1 (736) 0 (0) – –
Abbreviations: CI¼ confidence interval; OR¼ odds ratio; s.d.¼ standard deviation. aCases: patients diagnosed with cancer during the period 1 April 2005–30 September 2008
with no history of mental health problems in the year before cancer diagnosis; controls were age, gender and practice-matched patients with no cancer diagnosis in their medical
history. bNo statistics reported as age, gender and practice (urban/rural data is on practice level, not on patient level) were used for matching.
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prescription occurred evenly throughout the year after diagnosis,
with no discernible peak to indicate a time of particular
vulnerability or recognition. Treatment was mainly of brief
duration indicating that it might have been more symptomatic
(e.g., hypnotic or antipsychotic prescription) rather than diag-
nosis-specific (e.g., sufficient dose and long duration of anti-
depressant prescription).
Strengths and limitations
This study quantifies the primary care recorded incidence and
pattern of emotional distress in the year following a cancer
diagnosis. The data were derived from a large database of routine
general practice data capturing comprehensive information on
prescriptions. Matching by age, gender and location removed the
effects of these confounders. We were able to study newly incident
emotional distress by excluding, from case and control groups,
patients with a relevant diagnostic code or treatment in the year
before their index date. We used detailed prescribing data to
estimate treatment dose and duration and this included two
measures of treatment duration – one based on actual dates of
issue and one based on the sum of the durations of actual
regimens. We found no meaningful difference in duration by these
two methods (results available from the authors on request). Our
matched control group had an incidence of 0.6% for anxiety/
anxiolytics and 0.8% for depression/antidepressants, which is
consistent with other studies (Rait et al, 2009; Martin-Merino et al,
2010). These figures support the validity of our methods and
representativeness of the GPs and patients included in the data set.
There are several limitations with this study. Firstly, GPs do not
record diagnostic codes for all patients they see or treat for
common mental disorders. It is possible that GPs saw more
patients with emotional distress than were identified by diagnostic
codes, particularly patients who did not receive drug treatment.
Also, some individuals may have received psychological support
from non-general practice providers or organisations. Moreover,
in mental health research, diagnoses should be supported by
structured clinical interviews, such as the Structured Clinical
Interview for DSM-IV (First et al, 1996). Such interviews were
unlikely to have been conducted by GPs. Secondly, while GPs in
Scotland issue prescriptions through practice computer systems
and the volume of prescribing is reliable, the indication for
treatment is not available and can only be inferred. Our data
included tricyclic antidepressants, which are commonly (up to
70%) prescribed for non-psychiatric problems such as pain
management (Patten et al, 2007; Lockhart and Guthrie, 2011).
Some antipsychotics (e.g., prochlorperazine) might also be
prescribed for nausea (Roffman and Pirl, 2003). As such, it is
likely that our figures overestimate the incidence of drug treatment
for emotional distress. Thirdly, we excluded patients with pre-
existing emotional distress. Therefore, our results may underplay
the burden of emotional distress in people with cancer, as a cancer
diagnosis may exacerbate underlying psychological morbidity.
However, our rates indicate the considerable burden of ‘new’
emotional distress following a diagnosis of cancer.
Only very small numbers of newly incident cases or treatment
for alcohol-related disorders were identified and no meaningful
interpretation could be made of these. Although this study
described the cases identified or treated by their GP, it does not
include those who were not. Finally, a higher case : control
matching ratio (for example, up to 1 : 5) may have given us
slightly higher statistical power compared with the 1 : 2 ratio
achieved. The size of the database population did not permit this.
Relationship to other research
Prevalence rates of depression in cancer patients previously
reported from cross-sectional studies have been estimated to be
up to 40% (Massie, 2004). These increased rates in cancer patients
were found irrespective of cancer site (Miovic and Block, 2007).
Similar prevalence rates for anxiety have been described in cancer
patients. Our findings showed an overall incidence rate of
emotional distress of 15.6% (9.8% for depression and 7.4% for
anxiety) within 1 year following cancer diagnosis, which was much
greater than in the non-cancer population. It appears that GPs are
identifying and addressing emotional distress in people with
cancer, but no conclusions can be drawn from our data on whether
all incident cases were identified. Our results differ from the
Table 2 1 year incidence (and proportion of affected individuals identified by diagnostic code, prescription or both) of diagnosis of emotional distress with
ORs and the number of emotional distress categories per patient
Cases (n¼ 7298) % (n) Controls (n¼ 14 596) % (n) Total (n¼21 894) % (n) OR (95% CI)
Anxiety/Anxiolytics 7.4 (537) 0.6 (84) 2.8 (621) 14.32 (11.23–18.26)
READ code only 6.7 (37) 26.2 (22) 9.5 (59)
Anxiolytic drug use only 89.2 (479) 69.0 (58) 86.5 (537)
Both 3.9 (21) 4.8 (4) 4.0 (25)
Depression/Antidepressantsa 9.8 (713) 0.8 (112) 3.8 (825) 13.84 (11.24–17.03)
READ code only 2.0 (14) 9.8 (11) 3.4 (25)
Antidepressant use only 84.3 (601) 72.3 (81) 82.7 (682)
Both 13.7 (98) 17.9 (20) 14.3 (118)
Alcohol/Acamprosate/Disulfiram 0.8 (55) 0.2 (27) 0.4 (82) 4.07 (2.57–6.46)
READ code only 100.0 (55) 96.3 (26) 98.8 (81)
Acamprosate/Disulfiram 0 (0) 0 (0) 0 (0)
Both 0 (0) 3.7 (1) 1.2 (1)
Total number of persons with emotional distress 15.6 (1135) 1.4 (201) 6.1 (1336) 13.66 (11.59–16.11)
Number of emotional distress categories
1 85.1 (966) 89.1 (179) 85.7 (1145)
2 14.8 (168) 10.9 (22) 14.2 (190)
3 0.1 (1) 0 (0) 0.1 (1)
Abbreviations: CI¼ confidence interval; odds radio¼OR. aAntidepressant treatment may be used to treat anxiety disorders without depression: categories relate to diagnosis or
treatment class rather than accurate diagnosis.
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case–control study by Khan et al (2010), which showed no
significant increase of depression and anxiety in those surviving
for 5 years after a cancer diagnosis. The longer time since
diagnosis used in Khan’s study may have obscured rises in
emotional distress in the immediate post-diagnostic period which
subsequently resolved at the time of data collection. Furthermore,
the current study included patients who did not have such a good
prognosis (study period covers up to 1 year after cancer diagnosis)
as all cancer cases in the study of Khan (survival for at least 5
years).
Table 2 shows a small overlap between diagnostic codes and
psychotropic drug prescriptions. The majority of individuals
identified with emotional distress received a psychotropic drug
prescription without a diagnostic code. This might be due to
under-coding of mental health disorders in patients’ medical
records. Contextual and psychosocial circumstances might
influence a GP’s decision to prescribe an antidepressant but not
record a diagnostic code for depression. For example, GPs might
omit these codes believing significant distress in the face of a
cancer diagnosis to be ‘normal’ despite warranting treatment.
Alternatively, codes may be omitted to avoid stigmatising patients
or avoid a further diagnostic burden (Rait et al, 2009; Burton et al,
2012). The present data provide evidence that GPs are identifying
and managing emotional distress but not always recording it as a
diagnosis. In a time of increasing performance review, audit, and
guideline-driven care, there is a need for universal diagnostic
coding of all encounters. Our data suggests that the fixed terms
available within the READ V2 hierarchy may not always fit the
requirements of GPs in recording details of a consultation.
Clinicians may prefer free text (not assessed during this study)
or perhaps new codes appropriate to the cancer context should be
created?
Patients at later stages of cancer, who have more physical
symptoms or at specific times during their trajectory (such as
diagnosis, suspicious symptoms and beginning and starting
treatment) are at increased risk of distress (Madden, 2006). The
steady development of emotional distress throughout the first year
following diagnosis described in our study might be explained by
our heterogeneous sample with respect to cancer site, disease stage
and treatment.
The duration of anxiolytic prescriptions followed the clinical
guideline to use benzodiazepines for short term relief (2–4 weeks
only) (NICE, 2011). The drug group ‘hypnotics’ are not licensed
for long-term use but the median of 55 days (8 weeks) of use
among cases tended to exceed guideline recommendations of a
Table 3 Number of different psychotropic drugs per patient, different
psychotropic drug groups taken per patient and users within each drug
group taken by patients identified with a diagnosis of emotional distress and
with a psychotropic drug prescription in the 6 months after initial diagnosis
and/or prescription (n¼ 1227)
Cases
(n¼ 1066) % (n)
Controls
(n¼ 161) % (n) P
Number of psychotropic drugs
1 61.8 (659) 80.7 (130) o0.001
2 25.1 (268) 17.4 (28)
3 9.8 (104) 1.9 (3)
4 26 (2.4) 0 (0)
5 0.8 (8) 0 (0)
6 0.1 (1) 0 (0)
Number of psychotropic drug groups
1 64.1 (683) 85.1 (137) o0.001
2 28.2 (301) 13.7 (22)
3 7.0 (75) 1.2 (2)
4 0.7 (7) 0 (0)
Users within each drug group
Anxiolytics 46.5 (496) 37.9 (61) 0.040
Hypnotics 22.7 (242) 7.5 (12) o0.001
Antidepressants 64.9 (692) 62.7 (101) 0.589
Tricyclic
antidepressants
35.1 (374) 28.6 (46) 0.104
Other
antidepressants
33.5 (357) 36.6 (59) 0.430
Antipsychotics 8.8 (94) 6.2 (10) 0.268
Typical
antipsychotics
8.3 (89) 3.1 (5) 0.020
Atypical
antipsychotics
0.6 (6) 3.1 (5) 0.009a
Anti-manic 0.9 (14) 1.1 (2) 1.000a
Anti-alcohol 0 (0) 0.5 (1) 0.131a
aFisher’s Exact test was used instead of w2 due to low numbers in one or more cells.
Statistically significant results (Po0.05) are indicated in bold.
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Figure 2 Kaplan–Meier graphs illustrating the proportion of patients at
each time in 1 year after the index date with a first diagnosis and/or
prescription for (A) anxiety/anxiolytics, for (B) depression/antidepressants
and for (C) alcohol/acamprosate/disulfiram; the time to diagnosis and/or
prescription is expressed in days.
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few (2–4) weeks (2010). Clinical guidelines recommend the use of
antidepressants for 6 months after remission of depression (NICE,
2009). The median duration of antidepressant prescribing in this
study was 2 months. The number of patients with anti-manic and
anti-alcohol medicines was too low to draw any conclusions.
Implications for practice, policy and research
The small overlap of diagnostic coding with psychotropic
prescribing and the shorter antidepressant treatment duration
than that recommended in clinical guidelines might possibly point
towards under-recognition and/or under-treatment of major
depressive disorders in this patient population. The absence of a
clear temporal pattern of incident emotional distress in the cancer
trajectory indicates a need for clinician vigilance throughout the
first year from diagnosis. All health professionals, in primary and
secondary care, should be alert to emotional distress in patients
with cancer and ensure psychological health is discussed and
treated. Specific reference to the management of emotional distress
should be incorporated into follow-up guidelines for cancer
management.
Policy makers should address the need for improved coding of
diagnosis and management of emotional distress in newly
diagnosed cancer patients. While retaining an option for free text
for clinical purposes, GPs might be encouraged to use a flexible
coding system in which symptom codes for distress, such as low
mood, are used until patients clearly meet criteria for a major
depressive disorder. Another alternative would be to include a
code such as ‘distress related to cancer diagnosis’.
Further research is needed to explain the small overlap between
mental health diagnostic codes and psychotropic prescriptions and
the lower use of mental health diagnostic codes in general. Data
linkage with secondary care systems would provide more
comprehensive information about mental health service use by
cancer patients. Moreover, studying the patient perspective in
identifying and managing emotional distress after cancer diagnosis
would enable these current results to be put in context. Finally,
larger numbers of patients would be needed to study the extent of
excessive alcohol use in this population.
CONCLUSIONS
Cancer patients are at substantially higher risk of emotional
distress in the year following their cancer diagnosis. The
pharmacological treatment of emotional distress in primary care
tends to involve low doses of short duration. Incidence of
emotional distress was evenly spread throughout the year after
diagnosis with no time of particular vulnerability. Clinicians
should be vigilant for emotional distress in patients during the first
year following cancer diagnosis.
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